New Products In Brief
This article was originally published in The Gray Sheet
Boston Scientific’s Ion stent
You may also be interested in...
NuVasive and Delcath Systems appoint CEOs. Boston Scientific Corp. names senior medical director, rhythm management. Silk Road Medical Inc. appoints executive VP, global sales. Si-Bone taps CFO.
The singular U.S. market dominance of the cobalt-chromium everolimus-eluting stent known as Xience V or Promus is likely to be threatened next year as two new next-generation products make their way to market.
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.